Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will participate in three major conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, 2020, with a presentation on November 19 at 5:00 p.m. GMT. The SVB Leerink Oncology Day will occur on the same day. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for November 30 - December 3, 2020, with presentation availability starting on November 23. Webcasts will be available on Xencor's website after the events.
- None.
- None.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at three upcoming conferences:
-
Jefferies Virtual London Healthcare Conference
Conference Dates: November 17-19, 2020
Presentation Date: Thursday, November 19, 2020
Presentation Time: 5:00 p.m. GMT / 9:00 a.m. PST
-
SVB Leerink Oncology Day
Conference Date: Thursday, November 19, 2020
-
Piper Sandler 32nd Annual Virtual Healthcare Conference
Conference Dates: November 30 - December 3, 2020
Presentation Available: Monday, November 23, 2020
Webcasts of the Jefferies and Piper Sandler presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the live Jefferies presentation will be posted on the Xencor website approximately one hour after the live event. Both presentations will be available for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
